Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SGX Pharmaceuticals has submitted an investigational new drug application to the FDA for SGX523, an internally developed, orally-bioavailable, small molecule inhibitor of the cMET receptor tyrosine kinase.
Subscribe to our email newsletter
SGX523 has shown significant selectivity for the cMET receptor tyrosine kinase over more than 200 protein kinases and has demonstrated both potent in vitro blockade of the activity of this cancer target and in vivo activity against human cancer cells that depend on cMET for their uncontrolled growth and proliferation.
The company expects to begin Phase I clinical trials of SGX523 for solid tumor cancer patients in early 2008.
Mike Grey, president and CEO of SGX Pharmaceuticals, said: “We look forward to capitalizing on this positive momentum and initiating clinical studies in solid tumor cancer patients following FDA review of our submission.”